Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib and Camrelizumab in Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT04978012Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Jul 2021
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluzoparib and camrelizumab in nasopharyngeal carcinoma (NPC), sponsored by Fudan University. Primary endpoint: Overall Response Rate at 2 years. Started Jul 2021; status: recruiting.
02
Drugs
fluzoparibcamrelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04978012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04978012.